Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM823CD)

Drug Name

2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione Drug Info

Synonyms

CHEMBL176400; F2147-1072; 7351-91-9; 2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione; SCHEMBL14676513; MolPort-023-212-106; DEWGBLHKQDVWLX-UHFFFAOYSA-N; BDBM50291598; ZINC28090831; AKOS024627738; MCULE-2799628954; 2-(4-(diethylamino)but-2-yn-1-yl)isoindoline-1,3-dione

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 44385509
TTD Drug ID: DM823CD

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Muscarinic acetylcholine receptor M1 (CHRM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ACECLIDINE	DMOLNCZ	Glaucoma/ocular hypertension	9C61	Approved	[2]
Fesoterodine fumarate	DM13495	Overactive bladder	GC50.0	Approved	[3]
SMT-D002	DM1I93C	Seborrhea	ED91.2	Approved	[4]
Clidinium	DMUMQZ0	Abdominal stomach pain	DD91.4	Approved	[5]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[6]
Oxyphenonium	DMMQHOZ	Visceral spasms	MD81.4	Approved	[7]
Benztropine	DMGZOVN	Parkinson disease	8A00.0	Approved	[8]
Glycopyrrolate	DM2M3ZA	Anaesthesia	9A78.6	Approved	[9]
Pirenzepine	DMP6M1N	Peptic ulcer	DA61	Approved	[10]
Cycrimine	DM8C43Q	Parkinson disease	8A00.0	Approved	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Muscarinic acetylcholine receptor M2 (CHRM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ACECLIDINE	DMOLNCZ	Glaucoma/ocular hypertension	9C61	Approved	[2]
Methacholine Chloride	DMGS4QH	Asthma	CA23	Approved	[12]
SMT-D002	DM1I93C	Seborrhea	ED91.2	Approved	[4]
Methylscopolamine	DM5VWOB	Peptic ulcer	DA61	Approved	[13]
Gallamine Triethiodide	DMPO0MS	Stabilize muscle contraction	FB3Z	Approved	[14]
FP-1097	DMC1F2T	Urinary incontinence	MF50.2	Phase 2	[15]
PSD-506	DMT0KB1	Overactive bladder	GC50.0	Discontinued in Phase 2	[16]
Otenzepad	DMRXHAC	Heart failure	BD10-BD13	Discontinued in Phase 2	[17]
SCH-211803	DM92E0W	Parkinson disease	8A00.0	Discontinued in Phase 1	[18]
Alvameline	DMLN0Y5	Alzheimer disease	8A20	Terminated	[19]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Muscarinic acetylcholine receptor M1 (CHRM1)	TTZ9SOR	ACM1_HUMAN	Inhibitor	[1]
Muscarinic acetylcholine receptor M2 (CHRM2)	TTYEG6Q	ACM2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Design of dual acting anticonvulsant-antimuscarinic succinimide and hydantoin derivatives, Bioorg. Med. Chem. Lett. 7(8):979-984 (1997).
2	Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
5	Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460.
6	The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic dr... Psychopharmacology (Berl). 2009 Apr;203(2):295-301.
7	Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62.
8	Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60.
9	Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701.
10	Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31.
11	Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42.
12	6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55.
13	Methylacridinium and its cholinergic properties. Neurotox Res. 2009 Nov;16(4):372-7.
14	Cholinergic regulation of the corpora allata in adult male loreyi leafworm Mythimna loreyi. Arch Insect Biochem Physiol. 2002 Apr;49(4):215-24.
15	Clinical pipeline report, company report or official report of FemmePharma.
16	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
17	Beneficial effect of muscarinic-2 antagonist on dilated cardiomyopathy induced by autoimmune mechanism against muscarinic-2 receptor. J Cardiovasc Pharmacol. 2001 Oct;38 Suppl 1:S43-9.
18	Improving the oral efficacy of CNS drug candidates: discovery of highly orally efficacious piperidinyl piperidine M2 muscarinic receptor antagonists. J Med Chem. 2002 Dec 5;45(25):5415-8.
19	In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro. Psychopharmacology (Berl). 1998 Jun;137(3):233-40.